Pilot Study to Improve In Vitro Identification of Culprit Drugs in SJS/TEN Using Granzyme B and Granulysin Secretion Assays
Open Access
- 1 January 2026
- journal article
- Published by Wiley in Journal of Immunology Research
- Vol. 2026 (1) , 8497493
Abstract
Introduction: Stevens–Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) are severe cutaneous adverse drug reactions (SCARs) with high morbidity and mortality. Accurate identification of the culprit drug is critical and remains challenging, whereas current in vitro tests such as lymphocyte transformation test (LTT) have limited sensitivity. To evaluate measuring granulysin (Gr) and granzyme B (GZB) secretion from drug‐stimulated peripheral blood mononuclear cells (PBMCs) for identification of culprit drugs and to compare their diagnostic performance with conventional LTT. Materials and Methods: PBMCs from 12 patients with confirmed SJS/TEN were incubated with suspected drugs. LTT and Gr/GZB detection assays were performed on day 3 and 6. Levels of Gr and GZB were quantified from supernatants, and results were normalized as production ratios. Cut‐off values were defined using receiver operating characteristic (ROC) curve analysis with high specificity thresholds. Results: GZB detection on day 3 yielded the highest sensitivity (8/12) compared to LTT (6/12) and Gr detection. Combining GZB and Gr detection improved the positive rate to 10/12. ROC curve analysis demonstrated higher AUCs for cytokine assay than for LTT, particularly for GZB at day 3. Combining GZB and Gr detection with LTT did not significantly increase diagnostic yield. Conclusion: The detection of GZB and Gr production in PBMC cultures provided a more sensitive and specific method than the conventional LTT for identifying culprit drugs in SJS/TEN. In particular, GZB detection at day 3 provided a shorter assay duration, avoided radioactive labeling, and demonstrated superior diagnostic performance. This cytokine‐based approach may represent a practical and safer alternative to enhance drug causality assessment in patients with SCARs.Keywords
Funding Information
- Faculty of Medicine Siriraj Hospital, Mahidol University (R016333003)
This publication has 33 references indexed in Scilit:
- Extracellular Granzyme B Mediates the Degradation of Collagen XVII in Stevens–Johnson Syndrome/Toxic Epidermal NecrolysisJournal of Investigative Dermatology, 2025
- The mRNA expression and secretion of granzyme B are up-regulated via the histamine H2 receptor in human CD4+ T cellsInflammation Research, 2023
- Lymphocyte transformation test and cytokine detection assays: Determination of read out parameters for delayed-type drug hypersensitivity reactionsJournal of Immunological Methods, 2021
- Granulysin-Based Lymphocyte Activation Test for Evaluating Drug Causality in Antiepileptics-Induced Severe Cutaneous Adverse ReactionsJournal of Investigative Dermatology, 2021
- Evaluation of a lymphocyte transformation test and cytokine detection assay to identify phenytoin and carbamazepine provoked DRESS or SJS/TEN in epilepsy patientsInternational Immunopharmacology, 2018
- Cellular in vitro diagnosis of adverse drug reactionsAllergo Journal International, 2014
- Rapid immunochromatographic test for serum granulysin is useful for the prediction of Stevens-Johnson syndrome and toxic epidermal necrolysisJournal of the American Academy of Dermatology, 2011
- In Vitro Tests in Drug Hypersensitivity DiagnosisImmunology and Allergy Clinics of North America, 2009
- Granzyme B production distinguishes recently activated CD8+ memory cells from resting memory cellsCellular Immunology, 2007
- Clinical Classification of Cases of Toxic Epidermal Necrolysis, Stevens-Johnson Syndrome, and Erythema MultiformeArchives of Dermatology, 1993